Evidencia 13: The daily news

...

Pulse cell

America Movil, Carlos Slim, announced its intention to submit a claim to arbitration under NAFTA between Mexico and Colombia.

The company, whose subsidiary in Colombia is clear, seeks compensation for the alleged change in the rules of the game against the reversal of the cellular infrastructure.

Commerce Ministry sources confirmed that the company notified and its intention to report a violation of commitments.

The expert Martin Gustavo Ibarra recalled that the treaty with Mexico takes about 20 years and is very likely that most of the investments of Mexican origin are post-NAFTA, initially known as the G-3, as included Venezuela.

"What invokes the agreement is out of national jurisdiction and to call an international, including arbitration, which would be mandatory for Colombia, but always must be met before the conciliation stage," Ibarra said.

The case broke after the Ministry of ICT convene an arbitration tribunal after failing to reach a legal agreement with Claro and Movistar in the return process and infrastructure networks that were installed since 1994.

Delays in the wilderness

The Canadian mining company announced that Eco Oro accuse the country because its activities have been affected by the " excessive delay the Government in clarifying the boundaries of moor Santerían “.

This delay did not allow limits Renoirian whether the Angostura project, says the company, and highlights the "persistent to provide clarity as to the right of Eco Oro to continue the development of its mining project failure." It also mentions the decision of the Constitutional Court, which extended the ban on mining on the moors.

Asks multinational monetary compensation in light of an alleged breach of the FTA between Canada and Colombia.

Environmental organizations point that has been clear since the beginning of Angostura that the Constitution and other regulations protect the moors and, therefore, the project could not be authorized.

Patent pending decision

A recommendation from a committee of the Ministry of Health to lift a drug patent has alerted the pharmaceutical industry and could lead to another issue in the light of one of the TLC, experts say.

The drug Imatinib for leukemia, the firm Novartis of Switzerland could lose the patent. The Technical Committee of the Ministry of Health suggests that you can import the active ingredient for national laboratories produce it. The concept recommended to negotiate the price with the laboratory.

The so-called compulsory license is accepted by the World Trade Organization (WTO) for countries in special conditions, to grant patents for reasons of urgency and to be recognized mechanism.

But in the pharmaceutical industry consider that condition of urgency does not apply in this case.